BioCryst PharmaceuticalsBCRX
Recorded

BioCryst Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration42 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the BioCryst third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Nick Wilder with BioCryst.

Nick WilderInvestor Relations Manager

Nick, go ahead. Good morning, and welcome to BioCryst's third quarter 2026 corporate update and financial results conference call.

Nick WilderInvestor Relations Manager

Participating with me today are President and CEO Charlie Gayer, Chief Financial Officer Babar Ghias, and Chief R&D Officer Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our investor relations website. Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide two of the presentation. In addition, today's conference call includes non-GAAP financial measures.

Nick WilderInvestor Relations Manager

For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations website. I'd now like to turn the call over to Charlie.

Charlie GayerPresident and CEO

Thanks, Nick. The third quarter was significant for BioCryst as we continued to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for ORLADEYO continued at the same high level that we have seen all year. We again added new prescribers at a rate above the average of the past several years, and the total base of treated patients grew at a healthy rate in the quarter. We were thrilled to launch ORLADEYO pellets to kids in August, and early signs of performance continue to be promising. Children of all ages across the two to 11 range have started on ORLADEYO pellets, and the mix of kids switching from other prophy and acute only, as well as those who were treatment naive, has been balanced. This suggests the pediatric market may grow beyond the 500 patients that we have previously described.

Charlie GayerPresident and CEO

We are also looking forward to launching the recently approved 150 milligram ORLADEYO pellets at the upcoming American College of Allergy, Asthma, and Immunology meeting this month. This new formulation for ages 12 and up provides an option for kids who started on pellets, for adolescents and adults who have difficulty swallowing a capsule, or for anyone who simply prefers the pellet formulation. We are looking forward to generating real-world evidence to track the progress and patterns of use for all patients treated with ORLADEYO pellets. During the third quarter, we also implemented the transition to CareMed as our sole source pharmacy partner for shipments to patients. We switched to CareMed because the volume of patients on ORLADEYO has grown to the point where operational excellence at the pharmacy level can have a significant impact on the growth in treated patients and the shipment in paid product.

Charlie GayerPresident and CEO

We are working closely with CareMed to integrate best practices within our Empower Patient Services program and are encouraged by the early signs we are seeing in the partnership. We believe CareMed can scale with us as our portfolio of HAE prophy offerings continues to grow. Turning to our pipeline, as we have previously announced, the pivotal trial for navenibart fully enrolled in June, and we remain on track to announce top-line data through 12 months of therapy in the third quarter of next year. Our team is working diligently on the BLA file, as well as launch planning for when we add this potentially transformative product to our HAE portfolio. Continuing on the theme of strong execution, we have enrolled part four of our trial of BCX17725 for Netherton syndrome patients and are on track to have early clinical data by the end of this year.

Charlie GayerPresident and CEO

There are no treatments approved for this devastating skin condition that we believe includes at least 3,000 patients in the U.S. alone. Once the data reads out, we will review the data in totality, which includes key efficacy endpoints like IASI, the Ichthyosis Area and Severity Index score, as well as safety and tolerability to inform potential next steps in the program. Finally, we are excited about our strategic shift toward building our pipeline through external innovation. We recently announced a Scientific Advisory Board of leading biotech industry experts who will partner with us to deliver on our strategy. These esteemed advisors, with a successful track record, did not join us just for the honor of being on the board. They joined us because they believe that BioCryst's profitability, discipline, and strong execution position the company for success in our rare disease strategy.

Charlie GayerPresident and CEO

With that, I'll turn it over to Babar to describe our increasingly strong financial position.

Babar GhiasChief Financial Officer

Thanks, Charlie. We are pleased to share the results of a very strong third quarter, which included not only the important accomplishments just described, but also continued financial excellence. The intentional, proactive steps we have taken throughout the year to position BioCryst for durable growth and increasing profitability continue to be reflected in our financial performance. In my remarks today, I will refer to certain non-GAAP financial measures, which adjust for revenues and expenses associated with our former European ORLADEYO business, stock-based comp, Birmingham site closure, and organizational restructuring costs, and expenses associated with the Astria acquisition. Additional information regarding these adjustments is included in today's press release. We believe these non-GAAP measures provide investors with a useful view of the underlying performance of the ongoing business. Now, turning first to revenue. ORLADEYO net revenue was $174.8 million for the quarter, with more than 95% coming from the U.S. business.

Babar GhiasChief Financial Officer

On a comparable basis, excluding European revenue, ORLADEYO revenue increased 20% year over year. ORLADEYO revenues benefited this quarter from the CareMed transition. One of the benefits of switching to a larger specialty pharmacy is that they maintain a level of inventory at multiple sites and broader set of working operation hours that facilitate timely fulfillment to efficiently respond to patient demand. The inventory they hold typically ranges from one to three weeks of product. As part of the transition to this model, CareMed built an inventory level towards the lower end of this range during the third quarter, resulting in a revenue contribution in the upper teens of millions of dollars in the quarter. Since we expect their inventory level to remain in this lower end, revenue should more closely reflect underlying patient demand going forward.

Babar GhiasChief Financial Officer

While a transition of this nature naturally creates some temporary operational complexity as systems and processes are implemented, we are very pleased with the progress to date. Although it is still early, we are already seeing an improvement in days to first shipment for new patients, an important measure of the patient experience. Despite the transition, even when removing the impact of the inventory build, ORLADEYO revenue, excluding Europe, grew year over year. This is evidence of the continued favorable patient dynamics across the approved population. Throughout this process, our priority has remained the same, maintaining a high-quality patient experience and uninterrupted access to ORLADEYO. Before turning to operating expenses, let me briefly provide some context around the GAAP to non-GAAP adjustments this quarter. These adjustments primarily relate to the closure of our Birmingham facility and associated organizational restructuring activities that remain on track to be substantially completed by year-end.

Babar GhiasChief Financial Officer

Of the approximately $19 million in restructuring-related expenses in the quarter, only $10 million are real cash costs. Non-cash charges primarily reflected accounting adjustments to assets that no longer will have economic use following the closure. The most important takeaway today is the structural benefit to our cost base. The actions we have taken are expected to generate approximately $30 million-$35 million of annualized savings once fully realized, with the potential for additional savings as certain programs are wound down. As we look toward 2027, the business as it exists today is positioned for continued revenue growth alongside a lower operating cost base than in 2026. We will provide formal 2027 guidance at the appropriate time, but the combination should support continued expansion in profitability. Turning now over to operating expenses. Non-GAAP operating expenses were slightly lower year over year, consistent with the financial discipline we have been emphasizing.

Babar GhiasChief Financial Officer

We are actively investing in the phase III development program for navenibart, which is naturally an important driver of R&D spending. At the same time, we are taking a disciplined, data-driven approach to capital allocation across the rest of the pipeline. BCX17725 is a good example. Our approach has been to generate early clinical data in patients first, and let that data prospectively inform the appropriate level of future investment. We remain on track to share those data before year-end. Sales and marketing expenses were modestly higher year-over-year, driven primarily by the transition-related fees associated with the specialty pharmacy arrangement. G&A expense has remained essentially flat. This operating leverage from the trends is increasingly visible in our results.

Babar GhiasChief Financial Officer

Non-GAAP operating profit for the quarter was $86 million, an increase of 70% year-over-year, while non-GAAP net income of $71 million more than doubled from the prior year period. As profitability continues to grow, we also expect to benefit from our substantial net operating loss carryforwards, which should help limit cash taxes over the medium term, subject to applicable tax rules and limitations. That creates the potential for strong growth not only in earnings, but also in cash generation. Our liquidity position remains strong, with cash and equivalents of $376 million. As we have discussed, we have made a deliberate pivot toward external innovation, but we are going to remain disciplined in how we build the pipeline. For us, the priority is not adding programs simply to increase the size of the pipeline.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day